Zobrazeno 1 - 10
of 225
pro vyhledávání: '"OLIVER HOFFMANN"'
Autor:
Johannes Lübke, Nicole Naumann, Oliver Hoffmann, Hans-Peter Horny, Karl Sotlar, Martina Rudelius, Georgia Metzgeroth, Alice Fabarius, Wolf-Karsten Hofmann, Andreas Reiter, Juliana Schwaab
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract In 70 patients with KIT D816V positive systemic mastocytosis (SM) including 36 patients with advanced SM (AdvSM), we correlated the extent of reported mucosal mast cell ([m]MC) infiltration of the upper and/or lower gastrointestinal tract (U
Externí odkaz:
https://doaj.org/article/401bed6d276b43f0807e3552a3d9913f
Autor:
Stefanos Ioannis Moukas, Sabine Kasimir-Bauer, Mitra Tewes, Hans-Christian Kolberg, Oliver Hoffmann, Rainer Kimmig, Corinna Keup
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-17 (2023)
Abstract Biomarkers to identify metastatic breast cancer (mBC) patients resistant to CDK4/6 inhibition (CDK4/6i) are currently missing. We evaluated the usefulness of the monocyte-to-lymphocyte ratio (MLR), the neutrophil–to-lymphocyte ratio (NLR)
Externí odkaz:
https://doaj.org/article/b8426ff79ebb4e70beea6ba3dead165e
Autor:
Tom Degenhardt, Peter A. Fasching, Diana Lüftner, Volkmar Müller, Christoph Thomssen, Christian Schem, Isabell Witzel, Thomas Decker, Hans Tesch, Sherko Kümmel, Christoph Uleer, Rachel Wuerstlein, Oliver Hoffmann, Mathias Warm, Norbert Marschner, Timo Schinköthe, Ronald E. Kates, Johannes Schumacher, Burkhard Otremba, Matthias Zaiss, Nadia Harbeck, Marcus Schmidt, on behalf of the PreCycle Investigators
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targete
Externí odkaz:
https://doaj.org/article/3808c31034b14f1e8fdee7d4201422ec
Autor:
Oliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, Julian Hölzenbein, Esther Schwich, Sabine Schramm, Hana Rohn, Peter A. Horn, Rainer Kimmig, Sabine Kasimir-Bauer, Vera Rebmann
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionTriple negative breast cancer (TNBC) shows an aggressive growing and spreading behavior and has limited treatment options, often leading to inferior disease outcome. Therefore, surrogate markers are urgently needed to identify patients at
Externí odkaz:
https://doaj.org/article/1b610616dd9c4983a9d9f684f293205d
Autor:
Nils Martin Bruckmann, Julian Kirchner, Janna Morawitz, Lale Umutlu, Wolfgang P. Fendler, Ken Herrmann, Ann-Kathrin Bittner, Oliver Hoffmann, Tanja Fehm, Maike E. Lindemann, Christian Buchbender, Gerald Antoch, Lino M. Sawicki
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-14 (2022)
Abstract Background The free-breathing T1-weighted 3D Stack of Stars GRE (StarVIBE) MR sequence potentially reduces artifacts in chest MRI. The purpose of this study was to evaluate StarVIBE for the detection of pulmonary nodules in 18F-FDG PET/MRI.
Externí odkaz:
https://doaj.org/article/ffa5b62327dd4e018583caab4b600139
Autor:
Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, Andreas Schneeweiss
Publikováno v:
Breast, Vol 60, Iss , Pp 70-77 (2021)
Aim: The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German
Externí odkaz:
https://doaj.org/article/9d820c9a53514bca97c7dd4cdca4e33a
Autor:
Petra Huehnchen, Nikola Bangemann, Sandra Lischewski, Stefanie Märschenz, Friedemann Paul, Tanja Schmitz-Hübsch, Jens-Uwe Blohmer, Cornelia Eberhardt, Geraldine Rauch, Agnes Flöel, Sophie Adam, Philipp Schwenkenbecher, Ivo Meinhold-Heerlein, Oliver Hoffmann, Tjalf Ziemssen, Matthias Endres, Wolfgang Boehmerle
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionChemotherapy-induced polyneuropathy (CIPN) and post-chemotherapy cognitive impairment (PCCI) are frequent side effects of paclitaxel treatment. CIPN/PCCI are potentially irreversible, reduce quality of life and often lead to treatment lim
Externí odkaz:
https://doaj.org/article/6c31444432b745e89359363e4068f079
Autor:
Corinna Keup, Vinay Suryaprakash, Siegfried Hauch, Markus Storbeck, Peter Hahn, Markus Sprenger-Haussels, Hans-Christian Kolberg, Mitra Tewes, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Single liquid biopsy analytes (LBAs) have been utilized for therapy selection in metastatic breast cancer (MBC). We performed integrative statistical analyses to examine the clinical relevance of using multiple LBAs: matched circu
Externí odkaz:
https://doaj.org/article/39103299acfb493b841699ff8cdd9777
Autor:
Vera Rebmann, Esther Schwich, Rafael Tomoya Michita, Lisa Grüntkemeier, Ann-Kathrin Bittner, Hana Rohn, Peter A. Horn, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Despite major improvements in diagnostics and therapy in early as well as in locally advanced breast cancer (LABC), metastatic relapse occurs in about 20% of patients, often explained by early micro-metastatic spread into bone marrow by disseminated
Externí odkaz:
https://doaj.org/article/dbdf2d891d02448388189ee667f8d62f
Autor:
Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi, Arndt Hartmann
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8716 (2022)
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM5
Externí odkaz:
https://doaj.org/article/aed511032752487bac880db052f7203c